| __timestamp | BioMarin Pharmaceutical Inc. | Novo Nordisk A/S |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 26760000000 |
| Thursday, January 1, 2015 | 402271000 | 32169000000 |
| Friday, January 1, 2016 | 476593000 | 32339000000 |
| Sunday, January 1, 2017 | 554336000 | 32124000000 |
| Monday, January 1, 2018 | 604353000 | 33313000000 |
| Tuesday, January 1, 2019 | 680924000 | 35830000000 |
| Wednesday, January 1, 2020 | 737669000 | 36886000000 |
| Friday, January 1, 2021 | 759375000 | 41058000000 |
| Saturday, January 1, 2022 | 854009000 | 50684000000 |
| Sunday, January 1, 2023 | 937300000 | 61598000000 |
| Monday, January 1, 2024 | 67377000000 |
Igniting the spark of knowledge
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of leading companies is crucial. Novo Nordisk A/S and BioMarin Pharmaceutical Inc. have been at the forefront, showcasing distinct strategies in managing Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Novo Nordisk's SG&A expenses surged by approximately 130%, reflecting its aggressive expansion and marketing strategies. In contrast, BioMarin's expenses grew by about 210%, indicating its focus on scaling operations and market penetration. By 2023, Novo Nordisk's SG&A expenses were nearly 6.2 times higher than BioMarin's, highlighting its larger market footprint. This financial narrative not only underscores the strategic priorities of these pharmaceutical titans but also offers insights into their operational efficiencies and market positioning.
Novo Nordisk A/S or Vertex Pharmaceuticals Incorporated: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Novo Nordisk A/S vs ImmunityBio, Inc. Trends and Insights
Breaking Down SG&A Expenses: Novo Nordisk A/S vs Soleno Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Novo Nordisk A/S or MannKind Corporation
SG&A Efficiency Analysis: Comparing Novo Nordisk A/S and HUTCHMED (China) Limited
Johnson & Johnson and BioMarin Pharmaceutical Inc.: SG&A Spending Patterns Compared
AbbVie Inc. and BioMarin Pharmaceutical Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Bristol-Myers Squibb Company and BioMarin Pharmaceutical Inc.
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs Ultragenyx Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. vs Grifols, S.A.: SG&A Expense Trends
Selling, General, and Administrative Costs: BioMarin Pharmaceutical Inc. vs Ligand Pharmaceuticals Incorporated
Selling, General, and Administrative Costs: BioMarin Pharmaceutical Inc. vs Evotec SE